Loading quotes...
Forecast
| Buy |
1 |
| Hold |
0 |
| Sell |
0 |
Discussions in the community
- (✅) Split einer Aktie 1:10
Hallo! Die teure Schweizer Aktie Straumann ist getauscht worden-1:10! Wie kann ich das einarbeiten. Bis jetzt zeigt das System immer noch die falschen Werte an! Danke für die Hilfe!
Matthias Kaempfer I in Schnack 0 3
News Go to news feed
Straumann: CHF 10,000 ten years ago would be worth around CHF 24,300 today
Ten years ago the Straumann share closed at CHF 39.90; an investment of CHF 10,000 back then corresponds today to CHF 24,300.75 based on the closing price of CHF 96.96 and a performance of 143.01%. Market capitalization was most recently CHF 15.23 billion. Calculation does not account for stock splits or dividends. » More on finanzen.net
Straumann: CHF 1,000 ten years ago would be worth about CHF 2,502 today
An investor who bought CHF 1,000 of Straumann ten years ago would have received 25.957 shares at the time. With the last closing price of CHF 96.38, the investment would be worth CHF 2,501.75, an increase of 150.18 percent. The calculation does not take stock splits or dividends into account; Straumann was most recently quoted with a market value of CHF 15.51 billion. » More on finanzen.net
Straumann: five‑year investment would be about 49.6% down
If 100 CHF had been invested in Straumann five years ago, the held 0.532 shares at the price of 94.66 CHF would equal a value of 50.40 CHF, a loss of 49.60 percent. The earlier price was 187.80 CHF; the most recent market value is 15.19 billion CHF. Calculation does not take stock splits or dividends into account. » More on finanzen.net
Straumann rises after Goldman Sachs upgrade and raised price target
Straumann shares climbed 1.9% to CHF 95.9 after Goldman Sachs upgraded its rating from “Neutral” to “Buy” and raised the price target from CHF 106 to CHF 125. Goldman cited expected efficiency gains in production and operations and improved demand in the Asia-Pacific region as drivers for margin expansion through 2027. The bank forecasts adjusted EBIT growth of more than 20% in FY2027 and an average annual increase in free cash flow of 18% for 2026–2028. The upgrade follows earlier positive analyst comments from UBS and Barclays and stood out amid a weak broader market. » More on de.investing.com
Straumann share down over three years: CHF 10,000 investment lost 26.9%
A CHF 10,000 investment in Straumann three years ago would have fallen to CHF 7,310.94, representing a loss of 26.89%. The price fell from CHF 128.00 to CHF 93.58; market capitalization was most recently CHF 14.86 billion. The calculation does not account for stock splits or dividends. » More on finanzen.net
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 1.49bn | - |
| Gross profit | 1.06bn | - |
| Net profit | 270.07m | - |
| EBITDA | 456.86m | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €18.93bn |
Number of shares | 159.45m |
52-week high/low | €122.47 - €84.53 |
Dividend yield | 0.94% |
Dividends TTM | €1.09 |
Beta | 1.50 |
P/E ratio | 46.14 |
PEG ratio | -8.14 |
P/B ratio | 7.53 |
P/S ratio | 6.50 |
Company profile
Straumann Holding AG provides tooth replacement and orthodontic solutions worldwide. It researches, develops, manufactures, and supplies dental implants, instruments, CADCAM prosthetics, orthodontic aligners, biomaterials, and digital solutions for use in tooth correction, replacement, and restoration, as well as to prevent tooth loss. The company offers dental implant systems for tissue and bone level; titanium, titanium alloy, ceramic, and mini dental implant systems; and guided and non-guided surgical instruments, as well as implant-borne prosthetics. It provides ceramic healing and screw retained abutments; intraoral scanning solutions; 3D printers; milling machines; and prevention products. In addition, it offers biomaterials, bone substitutes, membranes, biologics, and soft tissue management and oral healing products; digital solutions for dental labs, dentists, and centralized milling centers, as well as materials, third party systems, and guided surgery; surgical instruments comprising surgical and modular cassettes, guided instruments, implant maintenance products, bone block fixation sets, bonerings, titanium pin sets, and other cassettes; and edentulous, pro arch fixed, prosthetic, and mini implant solutions for edentulous patients. Further, it provides esthetic restorations that include ceramic implant monotypes, ceramic implants, abutments, biologics, and other solutions; and Emdogain for wound healing. Further, it offers systems Clear Correct aligners; and training and education services to its customers. The company provides its products to general dentists, specialists, and dental technicians and laboratories, as well as corporate customers, such as distributors, hospitals, universities, and dental service organizations in approximately 100 countries through a network of distribution subsidiaries and partners. Straumann Holding AG was founded in 1954 and is headquartered in Basel, Switzerland.
| Name | Straumann Holding |
| CEO | Guillaume Daniellot |
| Headquarters | Basel,
bs Switzerland |
| Website | |
| Sector | Health Care |
| Industry | Health Care Technology |
| IPO | 17/07/1998 |
| Employees | 11,824 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Pnk | SAUHF |
SIX | STMN.SW |
Düsseldorf | QS51.DU |
London | 0QMV.L |